Menu
Menu
As soon as Opill® received its history-making FDA approval in July 2023, its makers, Perrigo, turned to us to create widespread interest in the imminent launch of the first OTC daily birth control pill and educate a consumer audience that likely had a lot of questions.
Being a first-of-its-kind product, Opill attracted massive public interest from its inception all the way through launch. Our team capitalized on the fact Opill’s availability was not only a milestone for reproductive health but also a cultural shift providing a new way of living. We also worked to create a strong emotional connection and fandom between the brand and our target audience, leading to a partnership with the WNBA. Following consistent earned media and social exposure, we saw massive impact from our efforts the week Opill first shipped.
6.2 billion media impressions from 700 articles; 2,500+ broadcast mentions, with 81% of coverage stemming from top-tier and local outlets
a nearly 900% increase in social conversations about Opill and over 1.1 billion brand impressions on social media
Sed aliquam ultrices mauris. Pellentesque dapibus hendrerit tortor. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos hymenaeos.
We’ve also been able to link stock price spikes to our PR activations, and we earned 147 pieces of coverage when we announced our WNBA partnership, generating over 1.3 billion impressions.
Take the next step and reach out today.
HAVAS Red
